Glioblastoma is the most common and aggressive primary brain tumour. However, not all intracranial tumours are glioblastomas:
percents of brain tumors
new cases per year worldwide
Very often, it is the general practitioner or the emergency doctor who, after having made an initial diagnosis, will prescribe the following examinations coupled with a consultation with a specialist (neurologists and neurosurgeons):
The median age at diagnosis is 65 years for men and 67 years for women in 2018.
The first step in treatment is often to remove as much of the tumor as possible. Surgery is almost always followed by radiation. To date, however, the various treatments have not prevented an almost systematic recurrence within 12 months.
The complexity and heterogeneity of glioblastomas have not allowed the emergence of therapeutic innovations in recent years, and their management has remained virtually unchanged for almost twenty years.
Currently, at Defymed and in collaboration with GlioCure, we are working on a treatment solution for glioblastoma.
The primary objective is to improve the quality of life of as many patients as possible, for whom ExOlin® combined with the GC01 peptide, developed by GlioCure, would represent a hope for a more effective therapy